Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-01-31
2006-01-31
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S423000, C514S006900, C514S772000, C514S777000, C514S785000, C514S788000, C530S399000
Reexamination Certificate
active
06992065
ABSTRACT:
A composition for sustained release comprises a carrier material containing a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37° C. that does not crytallize neat under ambient physiological conditions, a multivalent metal cation, and growth hormone.
REFERENCES:
patent: 4016273 (1977-04-01), Sieger et al.
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4938763 (1990-07-01), Dunn et al.
patent: 4975271 (1990-12-01), Dunn et al.
patent: 5077049 (1991-12-01), Dunn et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5133981 (1992-07-01), Harkrader et al.
patent: 5242910 (1993-09-01), Damanj
patent: 5278201 (1994-01-01), Dunn et al.
patent: 5278202 (1994-01-01), Dunn et al.
patent: 5324519 (1994-06-01), Dunn et al.
patent: 5324520 (1994-06-01), Dunn et al.
patent: 5340849 (1994-08-01), Dunn et al.
patent: 5368859 (1994-11-01), Dunn et al.
patent: 5411951 (1995-05-01), Mitchell
patent: 5487897 (1996-01-01), Polson et al.
patent: 5556905 (1996-09-01), Frappier et al.
patent: 5589167 (1996-12-01), Cleland et al.
patent: 5591713 (1997-01-01), Igari et al.
patent: 5599552 (1997-02-01), Dunn et al.
patent: 5651986 (1997-07-01), Brem et al.
patent: 5665394 (1997-09-01), Igari et al.
patent: 5747058 (1998-05-01), Tipton et al.
patent: 5780044 (1998-07-01), Yewey et al.
patent: 5783205 (1998-07-01), Berggren et al.
patent: 5851229 (1998-12-01), Lentz et al.
patent: 5889035 (1999-03-01), Strupczewski et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 5945115 (1999-08-01), Dunn et al.
patent: 5968542 (1999-10-01), Tipton
patent: 5972370 (1999-10-01), Eckenhoff et al.
patent: 5981489 (1999-11-01), Stevenson et al.
patent: 6039977 (2000-03-01), Venkatraman et al.
patent: 6051259 (2000-04-01), Johnson et al.
patent: 6051558 (2000-04-01), Burns et al.
patent: 6066619 (2000-05-01), Stevenson et al.
patent: 6080429 (2000-06-01), Cleland et al.
patent: 6087324 (2000-07-01), Igari et al.
patent: 6110503 (2000-08-01), Rickey et al.
patent: 6113943 (2000-09-01), Okada et al.
patent: 6113947 (2000-09-01), Cleland et al.
patent: 6120789 (2000-09-01), Dunn
patent: 6124261 (2000-09-01), Stevenson et al.
patent: 6130200 (2000-10-01), Brodbeck et al.
patent: 6143314 (2000-11-01), Chandrashekar et al.
patent: 6146662 (2000-11-01), Jao et al.
patent: 6165508 (2000-12-01), Tracy et al.
patent: 6174547 (2001-01-01), Dong et al.
patent: 6190700 (2001-02-01), Okada et al.
patent: 6191107 (2001-02-01), Yamagata et al.
patent: 6197350 (2001-03-01), Yamagata et al.
patent: 6245806 (2001-06-01), Dombrowski et al.
patent: 6267958 (2001-07-01), Andya et al.
patent: 6328979 (2001-12-01), Yamashita et al.
patent: 6413536 (2002-07-01), Gibson et al.
patent: 6429296 (2002-08-01), Yamagata et al.
patent: 6719992 (2004-04-01), Jeng et al.
patent: 0 216 485 (1987-04-01), None
patent: 0 484 387 (1994-01-01), None
patent: 173182 (1994-07-01), None
patent: WO 89/03671 (1989-05-01), None
patent: WO 92/17200 (1992-10-01), None
patent: WO 92-17200 (1992-10-01), None
patent: WO 94/12158 (1994-06-01), None
patent: WO 98/27962 (1998-07-01), None
patent: WO 98/27963 (1998-07-01), None
patent: WO 99/33491 (1999-07-01), None
patent: WO 00/38652 (2000-07-01), None
patent: WO 00/78335 (2000-12-01), None
patent: WO 01/28524 (2001-04-01), None
U. S. Provisional Application 60/214,168, filed Jun. 26, 2000.
Gray et al., “Cloning of Human Tumor Necrosis Factor (TNF) Receptor cDNA and Expression of Recombinant Soluble TNF-Binding Protein ”,Proc. Natl. Acad. Sci. USA, 87,7380-7384 (1990).
Kohno et al., “A Second Tumor Necrosis Factor Receptor Gene Product Can Shed a Naturally Occuring Tumor Necrosis Factor Inhibitor ”,Proc. Natl. Acad. Sci. USA, 87,8331-8335 (1990).
Arakawa et al., “Protein-Solvent Interactions in Pharmaceutical Formulations”,Pharmaceutical Research, 8,No. 3, 285-291 (1991).
Serge N. Timasheff, “The Control of Protein Stability and Association by Weak Interactions with Water: How Do Solvents Affect These Processes?”Annu. Rev. Biophys. Biomol. Struct., 22,67-97 (1993).
Kita et al., “Contribution of the Surface Free Energy Perturbation to Protein-Solvent Interactions ”,Biochemistry, 33,15178-15189(1994).
Serge N. Timasheff, “Solvent Stabilization of Protein Structure ”,Methods in Molecular Biology, 40,253-269 (1995).
Johnson et al., “A Month-Long Effect From a Single Injection of Microencapsulated Human Growth Hormone ”,Nature Medicine, 2,No. 7, 795-799 (1996).
Lin et al., “On the Role of Surface Tension in the Stabilization of Globular Proteins ”,Protein Science,5, 372-381 (1996).
Smith et al., “A Novel Parenteral Delivery System ”,Pharmaceutical Research, 13,No. 3, 300 (1996).
Xie et al., “The Thermodynamic Mechanism of Protein Stabilization by Trehalose ”,Biophysical Chemistry, 64,25-43 (1997).
Maa et al., “Spray-Drying of Air-Liquid Interface Sensitive Recombinant Human Growth Hormone”,Journal of Pharmaceutical Sciences, 87No. 2, 152-159 (1998).
Serge N. Timasheff, “Control of Protein Stability and Reactions by Weakly Interacting Cosolvents: The Simplicity of the Complicated”,Advances in Protein Chemistry, 51,355-432 (1998).
Sackett et al., “Multivalent Cations Depress Ligand Binding to Cell-Associated Insulin-Like Growth Factor Binding Protein-5 on Human Glioblastoma Cells”,Endocrinology, 139,No. 4, 1943-1951 (1998).
Lai et al., “Metal and RNA Binding Properties of the hdm2 Ring Finger Domain ”,Biochemistry, 37,No. 48, 17005-17015 (1998).
Yang et al., “Effect of Zinc Binding and Precipitation on Structures of Recombinant Human Growth Hormone and Nerve Growth Factor ”,Journal of Pharmaceutical Sciences, 89,No. 11, 1480-1485 (2000).
Bartus, et al., “Sustainted delivery of proteins for novel therapeutic agents”, (1998) Science, vol. 281, pp. 1161-1162.
Durect Corporation
Evan Law Group LLC
Genentech Inc.
Russel Jeffrey Edwin
LandOfFree
Sustained release formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3578422